Compare AdaptHealth Corp (AHCO) vs Nu Holdings Ltd (NU) Price & Performance

AdaptHealth (AHCO) trades at $5.63, up 7.85% today but remains under significant pressure after recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal negative profitability with a -6.82% net margin and three consecutive quarterly earnings misses. The company is restructuring by selling its diabetes unit to focus on sleep and respiratory care, but faces multiple securities fraud investigations following guidance revisions.

Despite 75% analyst buy ratings and an $11 consensus price target suggesting 95% upside, substantial risks exist including ongoing legal probes, execution challenges with new fixed-price contracts, and negative cash flow trends. The stock presents high-risk speculation amid operational restructuring and legal uncertainties.

NU stock trades at $13.47, down 2.81% over the past day, with technical indicators signaling a bearish trend. The company reported strong fundamentals, with revenue growing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent earnings have shown mixed results, with two misses in the last three quarters, but Q2 2026 results are anticipated as a potential catalyst. Analyst consensus remains bullish with a $14.98 price target, though technical weakness persists near support at $13.

The outlook for NU is supported by robust revenue growth and profitability improvements, but near-term risks include competitive pressures and technical bearishness. Upside potential exists if Q2 earnings beat expectations, while failure to meet targets could exacerbate selling pressure. Investors should weigh strong fundamentals against current market sentiment and upcoming earnings.